Eplerenone

Eplerenone has been studied in 16 papers since 2020: 3 trials and 6 observational studies in people, 3 in animals, 4 reviews; 13 in the past year. It is an approved medicine. The newest paper, Nov 9, 2026: “Clinical outcomes associated with angiotensin receptor–neprilysin inhibitors versus mineralocorticoid receptor antagonist initiation in patients with hypertension without heart failure: a propensity score–matched…”.

InterventionApproved 2002

16 papers study it6 more mention it7 findingsUpdated

PubChemChEBIMeSH

11 new papers in 30 daysSee all 22 papers on eplerenone

At a glance

The findings reach people, from one lab or study. 4 independent labs in 5 countries; 60 trials, 1 about aging, 18 with no results posted.

“Similarly, median change in eGFR was 0.0 mL/min/1.73m2 in both groups (p=0.71).”
Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trialESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.3057

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 4 independent labs in 5 countries
  • 60 trials, 1 about aging, 18 with no results posted
  • Funders: National Heart, Lung, and Blood Institute and 2 more
  • Human trial3
  • Humans6
  • Animals3

Studies in people

2 studies gave eplerenone to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on renal functionMedian eGFR change 0.0 mL/min/1.73m2 in both groups (p=0.71); median serum creatinine change 0.00 mg/dL in both groups (p=0.70)

no change: Has no effect on hyperkalemia1.2% versus 1.3% (p=1.00)

Randomized trial6 months162 peopleBoth30–75 yearsMidlife adults; Older adults; Obesity and essential hypertensionESC Congress 2026 abstract, Oct 26, 2026

up: Improves blood pressure control63.3% vs. 36.7%, p = 0.04

Randomized trial6 months60 peopleBoth58.4 yearsMidlife adults; stroke survivors with uncontrolled resistant hypertensionEquity neuroscience, Oct 16, 2025

What did studies of eplerenone find?

6

Studies of eplerenone measured 6 outcomes, among them pyridinoline and (iso)desmosine, lifespan and aortic aneurysm.

Pyridinoline and (iso)desmosine

upin mice1

1 study
  1. Eplerenone increases pyridinoline and (iso)desmosine in mice (Tgfb1L/L mice).

    AnimalsTgfb1L/L miceaorta

More on Pyridinoline and (iso)desmosine

Lifespan

upin mice1

1 study
  1. Eplerenone extends lifespan in mice (Tgfb1L/L mice).

    AnimalsTgfb1L/L micechronic

Aortic aneurysm

downin mice1

1 study
  1. Eplerenone prevents aortic aneurysm in mice (Tgfb1L/L mice).

    AnimalsTgfb1L/L miceaortachronic

More on Aortic aneurysm

Hyperkalemia

no changein humans1

1 study
  1. Eplerenone showed no clear effect on hyperkalemia in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (1.2% versus 1.3% (p=1.00)).

    Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162

More on Hyperkalemia

Renal function

no changein humans1

1 study
  1. Eplerenone showed no clear effect on renal function in humans (Obesity and essential hypertension; compared with irbesartan-based treatment) (Median eGFR change 0.0 mL/min/1.73m2 in both groups (p=0.71); median serum creatinine change 0.00 mg/dL in both groups (p=0.70)).

    Human trialObesity and essential hypertension; compared with irbesartan-based treatment25 mg twice daily6 monthsn = 162

Blood pressure control

upin humans1

1 study
  1. Eplerenone improves blood pressure control in humans (stroke survivors with uncontrolled resistant hypertension) (63.3% vs. 36.7%, p = 0.04).

    Human trialstroke survivors with uncontrolled resistant hypertension6 monthsn = 60

What is eplerenone linked with?

1

Studies link eplerenone with composite adverse cardiovascular events.

Composite adverse cardiovascular events

downin humans1HR 0.75

1 study
  1. Eplerenone lowers the risk of composite adverse cardiovascular events in humans (HR: 0.75, 95% CI: 0.64–0.88).

    Review4–44 monthsn = 54,964

Has eplerenone been tested in people?

1 of 60 about aging

Yes: 3 trials and 6 observational studies in people have been published, and 59 trials are registered.

Approved

  • FDA Inspra

    Sep 27, 2002Heart Failure, Hypertension, Myocardial Infarction, Myocardial Infarction, Acute, heart failure with reduced ejection fraction, high blood pressure, symptomatic heart failure

Repurposing

All 36

Every condition in trials

  • Pharmacodynamic

    Phase 4Completed2 trials

Stopped

  • NCT05129722TerminatedHeart failure with preserved ejection fraction

    Difficulties in recruitment at both sites.

  • NCT01971593TerminatedTetralogy of fallot

    Investigator left institution

  • NCT01708798TerminatedBreast neoplasm

    Futility

  • NCT04300881TerminatedVitreomacular traction

    Enrollment

Who is developing eplerenone?

1 company: Boehringer Ingelheim.

Companies
  • Boehringer IngelheimPhase 1diabetic nephropathies

Trial sponsors

Funding

1 grant since 2026

National Heart, Lung, and Blood Institute$773K

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 1Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 7Nov 2026: 517 papers in 12 months

See all 22 papers on eplerenone